Physiomics Marks Record Year with Expanding Consultancy and Personalized Medicine Initiatives

Proactive - Interviews for investors

Physiomics CEO Dr Peter Sargent joined Steve Darling from Proactive to highlighted the company’s significant progress, discussing a record-breaking fiscal year ending June 2024. The company’s strategy centers on two key areas: consultancy services in modeling, simulation, and data science, and personalized medicine software focused on optimizing oncology therapy dosing. One notable achievement includes a major contract with Cancer Research UK, bolstering Physiomics’ reputation in pharmacokinetic and pharmacodynamic (PK/PD) modeling. The company has recently onboarded a new head of quantitative pharmacology to drive its growth, generating valuable business leads. In personalized medicine, Physiomics is preparing a clinical trial to investigate further applications of its dosing tool for individualized cancer therapy, enhancing treatment precision. Dr. Sargent also noted the company's promising partnership with U.S.-based DoseMe, reflecting its international growth ambitions. “We’re growing the business,” Sargent stated, emphasizing ongoing enhancements to their product and service offerings to meet expanding demand in the precision medicine space. #proactiveinvestors #physiomicsplc #aim #pyc #PeterSargent #Biotech #Pharmaceuticals #PersonalizedMedicine #ClinicalTrials #DataScience #CancerResearch #PharmaInnovation #HealthcareTech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews